

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ultifend ND IBD concentrate and solvent for suspension for injection for chickens

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (0.05 ml or 0.2 ml) contains:

### Active substance:

Cell-associated live recombinant turkey herpesvirus (rHVT/ND/IBD), expressing the fusion protein of Newcastle disease virus and the VP2 protein of infectious bursal disease virus:  
min. 4,000, max. 12,000 PFU\*

\*Plaque forming units

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Concentrate and solvent for suspension for injection

Concentrate: yellowish brown homogeneous concentrate

Solvent: clear, orange to red solution

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Chickens and chicken embryonated eggs.

### 4.2 Indications for use, specifying the target species

For the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs:

- to reduce mortality, clinical signs and lesions caused by Newcastle disease virus (NDV) and to reduce virus shedding,
- to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (IBDV)
- to reduce mortality, clinical signs and lesions caused by classical Marek's disease virus (MDV).

### Onset of immunity:

Broiler chickens	NDV: 4 weeks IBDV: 3 weeks MDV: 9 days
------------------	--

Layer chickens	NDV: 4 weeks IBDV: 4 weeks MDV: 9 days
----------------	--

### Duration of immunity:

Broiler chickens	NDV: 9 weeks IBDV: 9 weeks MDV: life long
------------------	---

Layer chicken      NDV: 18 weeks  
                          IBDV: 9 weeks  
                          MDV: life long

#### **4.3 Contraindications**

None.

#### **4.4 Special warnings for each target species**

Vaccinate healthy animals only.

The onset of immunity for IBD in chickens with very high levels of maternally derived antibodies against IBDV or MDV may be delayed by about one week, when vaccinated with this veterinary medicinal product.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

Vaccinate all the chickens in a flock at the same time.

Vaccinated chickens may excrete the vaccine strain up to 49 days following vaccination. During this time, the contact of immunosuppressed and unvaccinated chickens with vaccinated chickens should be avoided.

The vaccine strain can spread to turkeys. Safety trials have shown that the excreted vaccine strain is not harmful in turkeys. However, appropriate veterinary and husbandry measures such as cleaning and disinfection procedures should be taken to avoid spread of the vaccine strain to turkeys.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Liquid nitrogen containers and vaccine should be handled by properly trained personnel only.

Personal protective equipment consisting of protective gloves, goggles and boots should be worn when handling the veterinary medicinal product, before withdrawing from liquid nitrogen, during the ampoule thawing and opening operations.

Frozen glass ampoules can explode during sudden temperature changes. Store and use liquid nitrogen only in a dry and well-ventilated place. Inhalation of the vapour of liquid nitrogen is dangerous.

Personnel involved in the treatment of vaccinated birds should use hygiene principles and take particular care in handling litter from vaccinated chickens.

#### **4.6 Adverse reactions (frequency and seriousness)**

None known.

#### **4.7 Use during pregnancy, lactation or lay**

##### Laying birds:

Do not use in birds in lay and within 4 weeks before the start of the laying period.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### 4.9 Amounts to be administered and administration route

*In ovo* and subcutaneous use.

*In ovo* administration: one dose of 0.05 ml to be administered to 18-day-old chicken embryonated eggs.

Subcutaneous administration: one dose of 0.2 ml to be administered to one-day-old chicken, in the skin of the neck.

##### Preparation of vaccine:

Use sterile devices and equipment for reconstitution and for administration of the vaccine. Before withdrawing vaccine from liquid nitrogen container, protect hands with gloves and use goggles and boots. When removing an ampoule from the strip, hold palm of gloved hand away from body and face.

1. After matching the dose size of the vaccine with the solvent size, quickly remove from liquid nitrogen container the exact number of ampoules needed.
2. Draw up 2 to 5 ml of solvent into a 5 to 10 ml sterile syringe. Use at least 18-gauge needles.
3. Thaw rapidly the contents of the ampoules by gentle agitation in water at 27-39°C.
4. As soon as they are completely thawed, open ampoules holding them at arm's length in order to prevent any risk of injury should the ampoule break.
5. Once the ampoule is open, slowly draw up the content into the needle already containing 2 to 5 ml solvent.
6. Transfer the suspension into the solvent bag. The diluted vaccine prepared as described is mixed by gentle agitation.
7. Withdraw a portion of the diluted vaccine into the syringe to rinse ampoule. Remove the washing from the ampoule and inject it gently into the solvent bag. Repeat it one or two times.
8. The diluted vaccine prepared as described is mixed by gentle agitation so as to be ready for use.

Repeat the operations in point 2 to 7 for the appropriate number of ampoules to be thawed.

The ready to use vaccine is a red, slightly opalescent liquid.

##### Proposed dilutions for *in-ovo* administration:

One single dose of 0.05 ml is injected into each 18-day-old chicken embryonated egg.

Number of vaccine vials	Solvent	Volume of one dose
4 x 2000 doses	400 ml	0.05 ml
2 x 4000 doses	400 ml	0.05 ml
4 x 4000 doses	800 ml	0.05 ml
5 x 4000 doses	1000 ml	0.05 ml
6 x 4000 doses	1200 ml	0.05 ml
8 x 4000 doses	1600 ml	0.05 ml

##### Proposed dilutions for subcutaneous administration:

One single injection of 0.2 ml per chick is applied at one day of age.

Number of vaccine vials	Solvent	Volume of one dose
-------------------------	---------	--------------------

2 x 1000 doses	400 ml	0.2 ml
1 x 2000 doses	400 ml	0.2 ml
1 x 4000 doses	800 ml	0.2 ml
3 x 2000 doses	1200 ml	0.2 ml
2 x 4000 doses	1600 ml	0.2 ml

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

No symptoms were observed after the administration of a 10-fold dose of vaccine.

#### **4.11 Withdrawal period(s)**

Zero days.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: immunologicals for Aves, live viral vaccines for domestic fowl.  
ATCvet code: QI01AD16

The vaccine contains a cell-associated, live recombinant herpesvirus of turkey (HVT, Marek's disease virus serotype 3) which is genetically modified to express the fusion (F) gene of Newcastle disease virus (NDV) and the virion protein (VP2) gene of infectious bursal disease virus (IBDV). The vaccine induces active immunity against Newcastle disease, infectious bursal disease (Gumboro disease) and Marek's disease.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

##### Concentrate:

EMEM  
L Glutamine  
Sodium bicarbonate  
Hepes  
Bovine serum  
Water for injections  
Dimethyl sulfoxide

##### Solvent:

Sucrose  
Casein hydrolysate  
Sorbitol  
Dipotassium hydrogen phosphate  
Potassium dihydrogen phosphate  
Phenol red  
Water for injections

#### **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product except the solvent (Cevac Solvent Poultry) supplied for use with the veterinary medicinal product.

#### **6.3 Shelf life**

Shelf life of the vaccine as packaged for sale: 18 months  
Shelf life of the solvent as packaged for sale: 30 months  
Shelf life after reconstitution according to directions: 2 hours.

#### **6.4. Special precautions for storage**

Concentrate:

Store and transport frozen in liquid nitrogen (-196°C).

The liquid nitrogen containers must be checked regularly for liquid nitrogen level and must be refilled as needed.

Solvent:

Store below 25°C.

Do not freeze.

#### **6.5 Nature and composition of immediate packaging**

Concentrate:

2 ml hydrolytic Type I glass ampoules, containing 1000, 2000 or 4000 doses.

The ampoules are put on canes with tag and stored in a liquid nitrogen container.

Solvent:

Plastic bags made of polyvinylchloride: 400 ml, 800 ml, 1000 ml, 1200 ml, 1600 ml.

Not all pack sizes may be marketed.

#### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

### **7. MARKETING AUTHORISATION HOLDER**

Ceva-Phylaxia Co. Ltd.  
1107 Budapest  
Szállás u. 5.  
Hungary

### **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/21/272/001-003

### **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: {DD/MM/YYYY}

### **10 DATE OF REVISION OF THE TEXT**

MM/YYYY

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**ANNEX II**

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**



**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND  
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance

Ceva-Phylaxia Co. Ltd.  
1107 Budapest  
Szállás u. 5.  
Hungary

Name and address of the manufacturers responsible for batch release

Ceva-Phylaxia Co. Ltd.  
1107 Budapest  
Szállás u. 5.  
Hungary

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

**C. STATEMENT OF THE MRLs**

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Ampoules of 1,000, 2,000 or 4,000 doses**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Ultifend ND IBD

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

rHVT/ND/IBD

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

1,000 doses  
2,000 doses  
4,000 doses

*(in the tag)*

**4. ROUTE(S) OF ADMINISTRATION**

SC or *in ovo* use.

**5. WITHDRAWAL PERIOD**

**6. BATCH NUMBER**

Lot {number}

*(and in the tag)*

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

CEVA-Phylaxia Co. Ltd.  
1107 Budapest  
Szállás u. 5.  
Hungary

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

Solvent bags of 400 ml, 800 ml, 1000 ml, 1200 ml, 1600 ml

**1. NAME OF THE DILUENT**

Cevac Solvent Poultry

**2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

400 ml  
800 ml  
1000 ml  
1200 ml  
1600 ml

**3. ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.

**4. STORAGE CONDITIONS**

Store below 25 °C.  
Do not freeze.

**5. BATCH NUMBER**

Lot {number}

**6. EXPIRY DATE**

EXP {month/year}

**7. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

Company logo

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET:

### Ultifend ND IBD concentrate and solvent for suspension for injection for chickens

#### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:

Ceva-Phylaxia Co. Ltd.  
1107 Budapest, Szállás u. 5.  
Hungary

#### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Ultifend ND IBD concentrate and solvent for suspension for injection for chickens

#### 3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT(S)

Each dose (0.05 ml or 0.2 ml) contains:

##### **Active substance:**

Cell-associated live recombinant turkey herpesvirus (rHVT/ND/IBD) expressing the fusion protein of Newcastle disease virus and the VP2 protein of infectious bursal disease virus min. 4,000, max. 12,000 PFU\*

\*Plaque forming unit

Concentrate: yellowish brown, homogeneous concentrate  
Solvent: clear, orange to red solution

#### 4. INDICATION(S)

For the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs:

- to reduce mortality, clinical signs and lesions caused by Newcastle disease virus (NDV) and to reduce virus shedding,
- to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (IBDV)
- to reduce mortality, clinical signs and lesions caused by classical Marek's disease virus (MDV).

##### Onset of immunity:

Broiler chickens	NDV: 4 weeks IBDV: 3 weeks MDV: 9 days
------------------	--

Layer chickens	NDV: 4 weeks IBDV: 4 weeks MDV: 9 days
----------------	--

##### Duration of immunity:

Broiler chickens,	NDV: 9 weeks
-------------------	--------------

IBDV: 9 weeks  
MDV: life long

Layer chicken,      NDV: 18 weeks  
                              IBDV: 9 weeks  
                              MDV: life long

## 5. CONTRAINDICATIONS

None.

## 6. ADVERSE REACTIONS

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Chickens and chicken embryonated eggs

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

*In ovo* and subcutaneous use.

*In ovo* administration: one dose of 0.05 ml to be administered to 18-day-old chicken embryonated eggs.

Subcutaneous administration: one dose of 0.2 ml to be administered to one-day-old chicken, in the skin of the neck.

Proposed dilutions for *in-ovo* administration:

One single dose of 0.05 ml is injected into each 18-day-old chicken embryonated egg.

Number of vaccine vials	Solvent	Volume of one dose
4 x 2000 doses	400 ml	0.05 ml
2 x 4000 doses	400 ml	0.05 ml
4 x 4000 doses	800 ml	0.05 ml
5 x 4000 doses	1000 ml	0.05 ml
6 x 4000 doses	1200 ml	0.05 ml
8 x 4000 doses	1600 ml	0.05 ml

Proposed dilutions for subcutaneous administration:

One single injection of 0.2 ml per chick is applied at one day of age.

Number of vaccine vials	Solvent	Volume of one dose
2 x 1000 doses	400 ml	0.2 ml
1 x 2000 doses	400 ml	0.2 ml
1 x 4000 doses	800 ml	0.2 ml
3 x 2000 doses	1200 ml	0.2 ml
2 x 4000 doses	1600 ml	0.2 ml



## **9. ADVICE ON CORRECT ADMINISTRATION**

### Preparation of vaccine:

Use sterile devices and equipment for reconstitution and for administration of the vaccine. Before withdrawing vaccine from liquid nitrogen container, protect hands with gloves and use goggles and boots. When removing an ampoule from the strip, hold palm of gloved hand away from body and face.

1. After matching the dose size of the vaccine with the solvent size, quickly remove from liquid nitrogen container the exact number of ampoules needed.
2. Draw up 2 to 5 ml of solvent into a 5 to 10 ml sterile syringe. Use at least 18-gauge needles.
3. Thaw rapidly the contents of the ampoules by gentle agitation in water at 27-39°C.
4. As soon as they are completely thawed, open ampoules holding them at arm's length in order to prevent any risk of injury should the ampoule break.
5. Once the ampoule is open slowly draw up the content into the needle already containing 2 to 5 ml solvent.
6. Transfer the suspension into the solvent bag. The diluted vaccine prepared as described is mixed by gentle agitation.
7. Withdraw a portion of the diluted vaccine into the syringe to rinse ampoule. Remove the washing from the ampoule and inject it gently into the solvent bag. Repeat it one or two times.
8. The diluted vaccine prepared as described is mixed by gentle agitation so as to be ready for use. Repeat the operations in point 2 to 7 for the appropriate number of ampoules to be thawed.

The ready to use vaccine is a red, slightly opalescent liquid.

## **10. WITHDRAWAL PERIOD(S)**

Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

### Concentrate:

Store and transport frozen in liquid nitrogen (-196°C).

The liquid nitrogen containers must be checked regularly for liquid nitrogen level and must be refilled as needed.

### Solvent (Cevac Solvent Poultry):

Store below 25°C.

Do not freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after {EXP}.

Shelf life after reconstitution according to directions: 2 hours.

## **12. SPECIAL WARNING(S)**

### Special warnings for each target species:

The onset of immunity for IBD in chickens with very high levels of maternally derived antibodies against IBDV or MDV may be delayed by about one week when vaccinated with this veterinary medicinal product.

Vaccinate healthy animals only.

#### Special precautions for use in animals

Vaccinate all the chickens in a flock at the same time.

Vaccinated chickens may excrete the vaccine strain up to 49 days following vaccination. During this time, the contact of immunosuppressed and unvaccinated chickens with vaccinated chickens should be avoided.

The vaccine strain can spread to turkeys. Safety trials have shown that the excreted vaccine strain is not harmful in turkeys. However, appropriate veterinary and husbandry measures such as cleaning and disinfection procedures should be taken to avoid spread of the vaccine strain to turkeys.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Liquid nitrogen containers and vaccine should be handled by properly trained personnel only.

Personal protective equipment consisting of protective gloves, goggles and boots should be worn when handling the veterinary medicinal product, before withdrawing from liquid nitrogen, during the ampoule thawing and opening operations.

Frozen glass ampoules can explode during sudden temperature changes. Store and use liquid nitrogen only in a dry and well-ventilated place. Inhalation of the vapour of liquid nitrogen is dangerous.

Personnel involved in the treatment of vaccinated birds should use hygiene principles and take particular care in handling litter from vaccinated chickens.

#### Lay:

Do not use in birds in lay and within 4 weeks before the start of the laying period.

#### Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### Overdose (symptoms, emergency procedures, antidotes):

No symptoms were observed after the administration of a 10-fold dose of vaccine.

#### Incompatibilities:

Do not mix with any other veterinary medicinal product except the solvent (Cevac Solvent Poultry) supplied for use with the veterinary medicinal product.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed via wastewater or household waste.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

DD/MM/YYYY

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

## **15. OTHER INFORMATION**

The vaccine contains a cell-associated, live recombinant herpesvirus of turkey (HVT, Marek's disease virus serotype 3) which is genetically modified to express the fusion (F) gene of Newcastle disease virus (NDV) and the virion protein (VP2) gene of infectious bursal disease virus (IBDV). The vaccine induces active immunity against Newcastle disease, infectious bursal disease (Gumboro disease) and Marek's disease.

Package size:

Concentrate: glass ampoules, containing 1000, 2000 or 4000 doses.

Cevac Solvent Poultry: 400 ml, 800 ml, 1000 ml, 1200 ml, 1600 ml in plastic bag.

Not all pack sizes may be marketed.